MedicalUpdateOnline’s Post

💫ONCOnews💫 🌟 Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study 👉 Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma 🔗 https://buff.ly/3Q0aMGr #OncEd #ONCOnews #OncoAlert

Highlighting Immunotherapy as first line treatment of advance Hodgkin disease A recent trial by Dr. Herrera from City of Hope compared first line treatment of advanced stage Hodgkin lymphoma patients with #Nivolumab or #Brentuximab combined with traditional AVD chemotherapy. The initial result after nearly two year follow-up of approximately 1000 patients showed better progression free survival in patients treated with #Nivolumab. N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin’s lymphoma and had a better side-effect profile. #Hodgkin #Nivolumab #Immunotherapy #Lymphoma https://lnkd.in/d58GVr8t

Small Bowel Lymphoma: Facts From "CT of Lymphoma: Involvement of the GI Tract - Part 1" View the full lecture here: https://lnkd.in/gKzpp8cz

Dr. Martin Dreyling presents results from the phase 3 ECHO trial at ASH 2024, evaluating the combination of acalabrutinib with bendamustine and rituximab in treating mantle cell lymphoma. This study demonstrated a significant improvement in PFS with a hazard ratio of 0.7 and a 10-15% increase in PFS rates. Although OS benefits were less clear due to the impact of the COVID-19 pandemic, the findings confirm that acalabrutinib improves outcomes, particularly for high-risk patients. 🔗 Read more about ASH 2024 here: https://lnkd.in/dCbc_vdV #ASH24 #Lymphoma #Treatment

Dr. Martin Dreyling presents results from the phase 3 ECHO trial at ASH 2024, evaluating the combination of acalabrutinib with bendamustine and rituximab in treating mantle cell lymphoma. This study demonstrated a significant improvement in PFS with a hazard ratio of 0.7 and a 10-15% increase in PFS rates. Although OS benefits were less clear due to the impact of the COVID-19 pandemic, the findings confirm that acalabrutinib improves outcomes, particularly for high-risk patients. 🔗 Read more about ASH 2024 here: https://lnkd.in/dV_KtyXJ #ASH24 #Lymphoma #Treatment

Two subtypes of cutaneous T-cell lymphoma (#CTCL) - Mycosis Fungoides and Sézary Syndrome - manifest and spread in different ways, including within the blood. Learn more at https://bit.ly/3Z9CSnR #BloodCancerAwarenessMonth

Dr. Martin Dreyling presents results from the phase 3 ECHO trial at ASH 2024, evaluating the combination of acalabrutinib with bendamustine and rituximab in treating mantle cell lymphoma. This study demonstrated a significant improvement in PFS with a hazard ratio of 0.7 and a 10-15% increase in PFS rates. Although OS benefits were less clear due to the impact of the COVID-19 pandemic, the findings confirm that acalabrutinib improves outcomes, particularly for high-risk patients. 🔗 Read more about ASH 2024 here: https://lnkd.in/dCN-yQw7 #ASH24 #Lymphoma #Treatment

#KiteNews: We announced findings from new analyses underscoring the curative potential of our CAR T-cell therapy for people living with relapsed/refractory large B-cell lymphoma at the American Society of Hematology Annual Meeting. The data included the largest real-world analysis of a broader patient population. #ASH24    Read more: https://bit.ly/3OK3SE3

INDUSTRY SPOTLIGHT UPDATE: Gilead agrees funding with Federal Government for Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for second-line treatment of relapsed or refractory large b-cell lymphoma Find out more here: t.ly/sCn1z #OncologyNews #CancerDrugUpdates #CARTcell #lymphoma #Yescarta

🚀 Discover Cutting-Edge Treatments: Delve into the role of 🧬 bispecific antibodies in R/R non-Hodgkin lymphoma. Sharpen your skills in administration, managing side effects, and integrating these therapies into care plans. Save Your Seat: http://ms.spr.ly/6048mogw8